@article{60f06832394a47ebb00c3710c9c43fea,
title = "Posttreatment Ischemic Lesion Evolution Is Associated With Reduced Favorable Functional Outcome in Patients With Stroke",
abstract = "Background and Purpose: Ischemic lesion volume can increase even 24 hours after onset of an acute ischemic stroke. In this study, we investigated the association of lesion evolution with functional outcome and the influence of successful recanalization on this association. Methods: We included patients from the MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) who received good quality noncontrast CT images 24 hours and 1 week after stroke onset. The ischemic lesion delineations included infarct, edema, and hemorrhagic transformation. Lesion evolution was defined as the difference between the volumes measured on the 1-week and 24-hour noncontrast CTs. The association of lesion evolution with functional outcome was evaluated using unadjusted and adjusted logistic regression. Adjustments were made for baseline, clinical, and imaging parameters that were associated P<0.10) in univariate analysis with favorable functional outcome, defined as modified Rankin Scale score of <= 2. Interaction analysis was performed to evaluate the influence of successful recanalization, defined as modified Arterial Occlusion Lesion score of 3 points, on this association. Results: Of the 226 patients who were included, 69 (31%) patients achieved the favorable functional outcome. Median lesion evolution was 22 (interquartile range, 10-45) mL. Lesion evolution was significantly inversely correlated with favourable functional outcome: unadjusted odds ratio, 0.76 (95% CI, 0.66-0.86; per 10 mL of lesion evolution; P<0.01) and adjusted odds ratio: 0.85 (95% CI, 0.72-0.97; per 10 mL of lesion evolution; P=0.03). There was no significant interaction of successful recanalization on the association of lesion evolution and favorable functional outcome (odds ratio, 1.01 [95% CI, 0.77-1.36]; P=0.94). Conclusions: In our population, subacute ischemic lesion evolution is associated with unfavorable functional outcome. This study suggests that even 24 hours after onset of stroke, deterioration of the brain continues, which has a negative effect on functional outcome. This finding may warrant additional treatment in the subacute phase.",
keywords = "edema, infarction, inflammation, ischemia, neuroprotection, outcome, INFARCT GROWTH, ENDOVASCULAR THERAPY, VOLUME, SCORE",
author = "P. Konduri and {van Voorst}, H. and A. Bucker and {van Kranendonk}, K. and A. Boers and K. Treurniet and O. Berkhemer and A.J. Yoo and {van Zwam}, W. and {van Oostenbrugge}, R. and {van der Lugt}, A. and D. Dippel and Y. Roos and J. Bot and C. Majoie and H. Marquering and {MR CLEAN Trial Investigators}",
note = "Funding Information: MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) is partly funded by the Dutch Heart Foundation (2008 T030). MR CLEAN is also funded by unrestricted grants from: AngioCare BV, Covidien/EV3, MEDAC Gmbh/LAMEPRO, Penumbra Inc, and Concentric Medical/TOP Medical BV. The study is designed, conducted, analyzed, and interpreted by the investigators independently of all sponsors. Funding Information: P. Konduri is funded by INSIST ( www.insist-h2020.eu ): a European Union{\textquoteright}s Horizon 2020 research and innovation programme (grant agreement number:777072). Dr van Voorst reports grants from Dutch Heart Foundation. Dr Boers is a shareholder of Nico.Lab. Dr Yoo reports grants from Cerenovus Neurovascular, Medtronic, Stryker, Penumbra, and Genentech for investigator-initiated studies; funds from Stryker, Cerenovus Neurovascular and Penumbra (core imaging lab activities) and Genentech (consultation); and declares to have equity ownership from Insera Therapeutics. Dr van Zwam reports speaker fees from Stryker and Cerenovus (paid to the institution). Dr van der Lugt and Dr Dippel report funds from the Cerenovus Neurovascular, Dutch Heart Foundation, Brain Foundation Netherlands, Organisation for Health Research and Development, Health Holland Top Sector Life Sciences & Health, and unrestricted grants paid to the institution from AngioCare BV, Covidien/EV3, MEDAC Gmbh/LAMEPRO, PenumbraInc, Top Medical/Concentric, Stryker, Stryker European Operations BV, Medtronic, Thrombolytic Science and LLC for research. A.van der Lugt further reports grants paid to the institution from the Siemens Healthineers, GE Healthcare and Philips Healthcare. Dr Roos is a shareholder at Nico-Lab. Dr Majoie reports grants from European Commission, during the conduct of the study; grants from CVON/Dutch Heart Foundation, grants from TWIN Foundation, grants from Stryker, outside the submitted work; and owns stock in Nico.lab. Dr Marquering is a cofounder and shareholder of Nico.lab. The other authors report no conflicts. Publisher Copyright: {\textcopyright} 2021 Lippincott Williams and Wilkins. All rights reserved.",
year = "2021",
month = nov,
day = "1",
doi = "10.1161/strokeaha.120.032331",
language = "English",
volume = "52",
pages = "3523--3531",
journal = "Stroke",
issn = "0039-2499",
publisher = "Wolters Kluwer Health",
number = "11",
}